Drug Profile
Research programme: small molecule therapeutics - Evotec SE/Institute of Medical Technology Magdeburg/KeyNeurotek AG
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Institute of Medical Technology Magdeburg; KeyNeurotek AG
- Developer Evotec SE; Institute of Medical Technology Magdeburg; KeyNeurotek Pharmaceuticals AG
- Class Skin disorder therapies; Small molecules
- Mechanism of Action CD13 antigen inhibitors; Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders; Immunological disorders; Metabolic disorders; Skin disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in CNS-disorders in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Immunological-disorders in Germany
- 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in Germany